Literature DB >> 34206200

Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management.

Jinghang Xu1, Qiao Zhan1, Yanan Fan1, Emily Kwun Kwan Lo2, Fangfei Zhang2, Yanyan Yu1, Hani El-Nezami2,3, Zheng Zeng1.   

Abstract

Liver cancer, predominantly hepatocellular carcinoma (HCC), is the third leading cause of cancer-related deaths worldwide. Emerging data highlight the importance of gut homeostasis in the pathogenesis of HCC. Clinical and translational studies revealed the patterns of dysbiosis in HCC patients and their potential role for HCC diagnosis. Research on underlying mechanisms of dysbiosis in HCC development pointed out the direction for improving the treatment and prevention. Despite missing clinical studies, animal models showed that modulation of the gut microbiota by probiotics may become a new way to treat or prevent HCC development.

Entities:  

Keywords:  dysbiosis; hepatocellular carcinoma; microbiota; probiotics

Year:  2021        PMID: 34206200     DOI: 10.3390/pathogens10070782

Source DB:  PubMed          Journal:  Pathogens        ISSN: 2076-0817


  59 in total

1.  Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats.

Authors:  Hui-Lu Zhang; Le-Xing Yu; Wen Yang; Liang Tang; Yan Lin; Han Wu; Bo Zhai; Ye-Xiong Tan; Lei Shan; Qiong Liu; Hai-Yang Chen; Rong-Yang Dai; Bi-Jun Qiu; Ya-Qin He; Chao Wang; Long-Yi Zheng; Yu-Qiong Li; Fu-Quan Wu; Zhong Li; He-Xin Yan; Hong-Yang Wang
Journal:  J Hepatol       Date:  2012-06-19       Impact factor: 25.083

2.  Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients.

Authors:  Haifeng Lu; Zhongwen Wu; Wei Xu; Jiezuan Yang; Yunbo Chen; Lanjuan Li
Journal:  Microb Ecol       Date:  2011-02-01       Impact factor: 4.552

3.  Response to: 'Circulating microbiome in blood of different circulatory compartments' by Schierwagen et al.

Authors:  Bastian Volker Helmut Hornung; Romy Danielle Zwittink; Quinten Raymond Ducarmon; Ed J Kuijper
Journal:  Gut       Date:  2019-04-06       Impact factor: 23.059

4.  Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis.

Authors:  M Grąt; K M Wronka; M Krasnodębski; Ł Masior; Z Lewandowski; I Kosińska; K Grąt; J Stypułkowski; S Rejowski; M Wasilewicz; M Gałęcka; P Szachta; M Krawczyk
Journal:  Transplant Proc       Date:  2016-06       Impact factor: 1.066

5.  Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.

Authors:  Raffaella M Gadaleta; Karel J van Erpecum; Bas Oldenburg; Ellen C L Willemsen; Willem Renooij; Stefania Murzilli; Leo W J Klomp; Peter D Siersema; Marguerite E I Schipper; Silvio Danese; Giuseppe Penna; Gilles Laverny; Luciano Adorini; Antonio Moschetta; Saskia W C van Mil
Journal:  Gut       Date:  2011-01-17       Impact factor: 23.059

6.  The human tumor microbiome is composed of tumor type-specific intracellular bacteria.

Authors:  Deborah Nejman; Ilana Livyatan; Garold Fuks; Noam Shental; Ravid Straussman; Nancy Gavert; Yaara Zwang; Leore T Geller; Aviva Rotter-Maskowitz; Roi Weiser; Giuseppe Mallel; Elinor Gigi; Arnon Meltser; Gavin M Douglas; Iris Kamer; Vancheswaran Gopalakrishnan; Tali Dadosh; Smadar Levin-Zaidman; Sofia Avnet; Tehila Atlan; Zachary A Cooper; Reetakshi Arora; Alexandria P Cogdill; Md Abdul Wadud Khan; Gabriel Ologun; Yuval Bussi; Adina Weinberger; Maya Lotan-Pompan; Ofra Golani; Gili Perry; Merav Rokah; Keren Bahar-Shany; Elisa A Rozeman; Christian U Blank; Anat Ronai; Ron Shaoul; Amnon Amit; Tatiana Dorfman; Ran Kremer; Zvi R Cohen; Sagi Harnof; Tali Siegal; Einav Yehuda-Shnaidman; Einav Nili Gal-Yam; Hagit Shapira; Nicola Baldini; Morgan G I Langille; Alon Ben-Nun; Bella Kaufman; Aviram Nissan; Talia Golan; Maya Dadiani; Keren Levanon; Jair Bar; Shlomit Yust-Katz; Iris Barshack; Daniel S Peeper; Dan J Raz; Eran Segal; Jennifer A Wargo; Judith Sandbank
Journal:  Science       Date:  2020-05-29       Impact factor: 47.728

7.  Targeting gut flora to prevent progression of hepatocellular carcinoma.

Authors:  Marion Darnaud; Jamila Faivre; Nicolas Moniaux
Journal:  J Hepatol       Date:  2012-08-30       Impact factor: 25.083

Review 8.  Bile acids: regulation of apoptosis by ursodeoxycholic acid.

Authors:  Joana D Amaral; Ricardo J S Viana; Rita M Ramalho; Clifford J Steer; Cecília M P Rodrigues
Journal:  J Lipid Res       Date:  2009-05-05       Impact factor: 5.922

9.  Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors.

Authors:  Motoo Nomura; Ryosuke Nagatomo; Keitaro Doi; Juko Shimizu; Kiichiro Baba; Tomoki Saito; Shigemi Matsumoto; Koichi Inoue; Manabu Muto
Journal:  JAMA Netw Open       Date:  2020-04-01

10.  Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.

Authors:  Svenja Sydor; Jan Best; Insa Messerschmidt; Paul Manka; Ramiro Vilchez-Vargas; Susanne Brodesser; Christina Lucas; Annemarie Wegehaupt; Chiara Wenning; Sophia Aßmuth; Simon Hohenester; Alexander Link; Klaas Nico Faber; Han Moshage; Francisco Javier Cubero; Scott L Friedman; Guido Gerken; Michael Trauner; Ali Canbay; Lars P Bechmann
Journal:  Clin Transl Gastroenterol       Date:  2020-03       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.